Kobayashi in $3.2 Billion Buyout Talks After Red-Yeast Case
Kobayashi Pharmaceutical Co. is reportedly considering a buyout offer of over $3.2 billion from private equity investors following a supplement contamination scandal.
Kobayashi Pharmaceutical Co., the Japanese health products company that was at the center of a supplement contamination scandal involving suspected deaths, is said to be considering a potential buyout offer of more than ¥500 billion ($3.2 billion) by private equity investors.
READ NEXT
More on the wire
AI TLDR
Utah prosecutors have dropped the death penalty for 71-year-old Douglas Stewart Carter. The decision follows new DNA evidence that excluded him from a 1985 murder case.
AI TLDR
Tesla has begun volume production of its heavy-duty Semi truck, nearly a decade after its initial 2017 concept introduction. The company held an event to demonstrate the vehicle to customers and investors.
AI TLDR
Shoppers at 7-Eleven stores in California are being warned to check their receipts carefully. Reports indicate a checkout error is causing customers to be charged triple the advertised price for items.